{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:40Z","timestamp":1786993480044,"version":"build-2736575974"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jsps.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T19:07:54Z","timestamp":1665256074000},"page":"1736-1747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies"],"prefix":"10.1007","volume":"30","author":[{"given":"Sivakumar S.","family":"Moni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Al Basheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1586\/eci.11.27","article-title":"Mepolizumab in eosinophilic disorders","volume":"7","author":"Abonia","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.jsps.2022.10.002_b0010","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1074\/jbc.275.6.3729","article-title":"Cystic fibrosis transmembrane conductance regulator. Structure and function of an epithelial chloride channel","volume":"275","author":"Akabas","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsps.2022.10.002_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2049-6958-9-23","article-title":"Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review","volume":"9","author":"Al Maghamsi","year":"2014","journal-title":"Multidiscip. Respir. Med."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5144\/0256-4947.2020.321","article-title":"Cystic fibrosis gene mutations and polymorphisms in Saudi men with infertility","volume":"40","author":"Al Maghamsi","year":"2020","journal-title":"Ann. Saudi Med."},{"issue":"7","key":"10.1016\/j.jsps.2022.10.002_b0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/pharmaceutics12070616","article-title":"Cystic fibrosis: Overview of the current development trends and innovative therapeutic strategies","volume":"12","author":"Almughem","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.jsps.2022.10.002_b0030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpam.2019.12.002","article-title":"Geographic distribution of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Saudi Arabia","volume":"8","author":"Banjar","year":"2021","journal-title":"Int. J. Pediatr. Adolesc."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpam.2015.05.006","article-title":"The road for survival improvement of cystic fibrosis patients in Arab countries","volume":"2","author":"Banjar","year":"2015","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0045","doi-asserted-by":"crossref","first-page":"637948","DOI":"10.3389\/fimmu.2021.637948","article-title":"Modulating Th2 Cell Immunity for the Treatment of Asthma","volume":"12","author":"Beatriz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jsps.2022.10.002_b0050","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1569-1993(11)60018-0","article-title":"Pharmacological therapy for cystic fibrosis: from bench to bedside","volume":"Suppl. 2","author":"Becq","year":"2011","journal-title":"J. Cyst Fibros."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0055","first-page":"27","article-title":"Omalizumab: A monoclonal anti-IgE antibody","volume":"7","author":"Belliveau","year":"2005","journal-title":"Med. Gen. Med."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1165\/ajrcmb.19.2.3053","article-title":"Interleukin-8 production by cystic fibrosis nasal epithelial cells after tumor necrosis factor-alpha and respiratory syncytial virus stimulation","volume":"19","author":"Black","year":"1998","journal-title":"Am. J, Respir Cell Mol. Biol."},{"key":"10.1016\/j.jsps.2022.10.002_b0065","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2013correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum. Mutat."},{"issue":"6","key":"10.1016\/j.jsps.2022.10.002_b0070","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jpeds.2009.09.001","article-title":"Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis","volume":"155","author":"Borowitz","year":"2009","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0075","doi-asserted-by":"crossref","first-page":"e00696","DOI":"10.1002\/rcr2.696","article-title":"Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis","volume":"9","author":"Boyle","year":"2020","journal-title":"Respirol. Case Rep."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1165\/rcmb.4898","article-title":"Pseudomonas aeruginosa induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator","volume":"29","author":"Cannon","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.jsps.2022.10.002_b0085","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.anai.2020.08.248","article-title":"M202 Benralizumab for management of ABPA in a CF patient","volume":"125","author":"Canon","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11739-017-1773-y","article-title":"Biologic agents for severe asthma patients: clinical perspectives and implications","volume":"13","author":"Caruso","year":"2018","journal-title":"Intern. Emerg. Med."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0095","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2016.12.047","article-title":"Omalizumab treatment in patients with cystic fibrosis (CF) and allergic bronchopulmonary aspergillosis (ABPA): A Case Series","volume":"139","author":"Castro-Wagner","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jsps.2022.10.002_b0100","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2147\/TCRM.S147164","article-title":"Triplet CFTR modulators: Future prospects for treatment of cystic fibrosis","volume":"14","author":"Chaudary","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"10","key":"10.1016\/j.jsps.2022.10.002_b0105","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1172\/JCI125669","article-title":"IL-1\u03b2 dominates the promucin secretory cytokine profile in cystic fibrosis","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","article-title":"Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis","volume":"63","author":"Cheng","year":"1990","journal-title":"Cell"},{"issue":"9998","key":"10.1016\/j.jsps.2022.10.002_b0115","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.jsps.2022.10.002_b0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0125","doi-asserted-by":"crossref","unstructured":"Colombo, C., Ellemunter H., Houwen, R., Munck, A., Taylor, C., A new initiative on precision medicine Wilschanski M., 2011. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J. Cyst. Fibros., 10(Suppl 2), S24-S28. https:\/\/doi.org\/10.1016\/S1569-1993(11)60005-2.","DOI":"10.1016\/S1569-1993(11)60005-2"},{"issue":"11","key":"10.1016\/j.jsps.2022.10.002_b0130","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/genes9110538","article-title":"Cystic fibrosis gene therapy: looking back, looking forward","volume":"9","author":"Cooney","year":"2018","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1755-7682-1-24","article-title":"Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers","volume":"1","author":"Coutinho","year":"2008","journal-title":"Int. Arch. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2049-6958-9-23","article-title":"Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review","volume":"9","author":"D\u2019Amato","year":"2014","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1710-1492-9-39","article-title":"The effects of rituximab on serum IgE and BAFF","volume":"9","author":"Dasgupta","year":"2013","journal-title":"All. Asth. Clin. Immun."},{"issue":"17","key":"10.1016\/j.jsps.2022.10.002_b0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.21037\/atm.2018.06.48","article-title":"Molecular basis of cystic fibrosis: from bench to bedside","volume":"6","author":"Dechecchi","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41434-022-00347-0","article-title":"Splicing mutations in the CFTR gene as therapeutic targets","volume":"29","author":"Deletang","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.jsps.2022.10.002_b0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3389\/fphar.2018.01381","article-title":"Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic","volume":"9","author":"Donnelley","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jsps.2022.10.002_b0165","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1203\/00006450-198410000-00018","article-title":"A monoclonal antibody recognizes structural variation in cystic fibrosis \u03b12-Macroglobulin","volume":"18","author":"Eager","year":"1984","journal-title":"Pediatr Res."},{"issue":"S1","key":"10.1016\/j.jsps.2022.10.002_b0170","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/ppul.24965","article-title":"Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF","volume":"56","author":"Egan","year":"2021","journal-title":"Pediatr. Pulmonol."},{"issue":"12","key":"10.1016\/j.jsps.2022.10.002_b0175","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jmg.34.12.996","article-title":"Novel and characteristic CFTR mutations in Saudi Arab children with severe cystic fibrosis","volume":"34","author":"el-Harith","year":"1997","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.jsps.2022.10.002_b0180","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618808490","article-title":"Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience","volume":"12","author":"Emma","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.jsps.2022.10.002_b0185","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/cells9030754","article-title":"Phenotyping of rare CFTR mutations reveals distinct trafficking and functional defects","volume":"9","author":"Ensinck","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jsps.2022.10.002_b0190","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620961648","article-title":"Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review","volume":"14","author":"Eraso","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mcp.2004.03.005","article-title":"A comparison of 14 antibodies for the biochemical detection of the cystic fibrosis transmembrane conductance regulator protein","volume":"18","author":"Farinha","year":"2004","journal-title":"Mol. Cell Probes."},{"issue":"9","key":"10.1016\/j.jsps.2022.10.002_b0200","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"21","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jsps.2022.10.002_b0205","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Fernando","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2009.03167.x","article-title":"Natural killer cells in infection and inflammation of the lung","volume":"128","author":"Fiona","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jsps.2022.10.002_b0215","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1089\/hum.2005.16.921","article-title":"Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy","volume":"16","author":"Flotte","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.jsps.2022.10.002_b0220","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1021\/acsami.1c14975","article-title":"Hybrid Lipid\/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?","volume":"14","author":"Gemma","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"8","key":"10.1016\/j.jsps.2022.10.002_bib548","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Giovanni","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0225","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/0019-5154.160490","article-title":"Omalizumab-A Review","volume":"60","author":"Godse","year":"2015","journal-title":"Indian J. Dermatol."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0230","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-05912-3","article-title":"Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India","volume":"21","author":"Gokhale","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jsps.2022.10.002_b0235","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/MCP.0000000000000327","article-title":"Cystic fibrosis gene therapy: a mutation-independent treatment","volume":"22","author":"Griesenbach","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"9","key":"10.1016\/j.jsps.2022.10.002_b0240","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-021-01299-x","article-title":"Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19","volume":"35","author":"Gritti","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jsps.2022.10.002_b0245","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jsps.2022.10.002_b0250","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s42399-021-00756-z","article-title":"The Epidemiology of cystic fibrosis in Arab Countries: A Systematic Review","volume":"3","author":"Hammoudeh","year":"2021","journal-title":"SN. Compr. Clin. Med."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5144\/0256-4947.2020.15","article-title":"Genotype patterns for mutations of the cystic fibrosis transmembrane conductance regulator gene: a retrospective descriptive study from Saudi Arabia","volume":"40","author":"Hanaa","year":"2020","journal-title":"Ann. Saudi Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0022-1759(86)90109-2","article-title":"Monoclonal antibodies to cystic fibrosis antigen","volume":"91","author":"Hayward","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jsps.2022.10.002_bib547","doi-asserted-by":"crossref","unstructured":"Hector, G. O. Mark, C. L., Ian, D.P., Guy, G.B., Mark FitzGerald, J., Alfredo, C., et al., 2014. Mepolizumab Treatment in Patients with Severe Eosinophilic asthma. N. Engl. J. Med., 371, 1198-1207. https:\/\/doi.org\/10.1056\/NEJMoa1403290","DOI":"10.1056\/NEJMoa1403290"},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0265","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatr. Respir. Rev."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_bib546","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2016.12.047","article-title":"Omalizumab treatment in patients with cystic fibrosis (CF) and allergic bronchopulmonary aspergillosis (ABPA): A Case Series","volume":"139","author":"Johana","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jsps.2022.10.002_b0270","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/biom5031386","article-title":"Transcription of Interleukin-8: How altered regulation can affect cystic fibrosis lung disease","volume":"5","author":"Jundi","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.jsps.2022.10.002_b0275","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fphar.2012.00201","article-title":"Mechanisms of CFTR folding at the endoplasmic reticulum","volume":"3","author":"Kim","year":"2012","journal-title":"Front Pharmacol."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0285","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/19420862.2016.1264551","article-title":"Validation of antibody reagents for mucin analysis in chronic inflammatory airway diseases","volume":"9","author":"Krause","year":"2017","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0290","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-016-0489-2","article-title":"End-stage cystic fibrosis lung disease is characterised by a diverse inflammatory pattern: an immunohistochemical analysis","volume":"18","author":"Lammertyn","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.jsps.2022.10.002_b0295","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","article-title":"Gene therapy for cystic fibrosis: new tools for precision medicine","volume":"19","author":"Lee","year":"2021","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.jsps.2022.10.002_b0300","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/protein\/gzm065","article-title":"A monoclonal antibody prevents aggregation of the NBD1 domain of the cystic fibrosis transmembrane conductance regulator","volume":"20","author":"Lovato","year":"2007","journal-title":"Protein Eng. Des. Sel."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0305","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2016.10.011","article-title":"The impact of impaired macrophage functions in cystic fibrosis disease progression","volume":"16","author":"Manuella","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/BF01955527","article-title":"Cystic fibrosis presenting with recurrent vomiting and metabolic alkalosis","volume":"150","author":"Mathew","year":"1991","journal-title":"Eur. J. Pediatr."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0315","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/ACI.0000000000000284","article-title":"Biologic therapy in the management of asthma","volume":"16","author":"McCracken","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"7\u20138","key":"10.1016\/j.jsps.2022.10.002_b0320","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbadis.2010.04.005","article-title":"Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis","volume":"1802","author":"McGreal","year":"2010","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.jsps.2022.10.002_b0325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2004.05.016","article-title":"Antibodies for CFTR studies","volume":"2","author":"Mendes","year":"2004","journal-title":"J. Cyst. Fibros Suppl."},{"issue":"7","key":"10.1016\/j.jsps.2022.10.002_b0330","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ppul.22890","article-title":"KB001 Study Group. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection","volume":"49","author":"Milla","year":"2014","journal-title":"Pediatr. Pulmonol."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0335","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/039463200802100410","article-title":"Tumor necrosis factor-alpha in airway secretions from cystic fibrosis patients upregulate endothelial adhesion molecules and induce airway epithelial cell apoptosis: implications for cystic fibrosis lung disease","volume":"21","author":"Mitola","year":"2008","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.jsps.2022.10.002_b0340","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2014.02.003","article-title":"Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control","volume":"108","author":"Molimard","year":"2014","journal-title":"Respir. Med."},{"issue":"8","key":"10.1016\/j.jsps.2022.10.002_b0345","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14728222.2018.1501361","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease","volume":"22","author":"Moore","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"issue":"Suppl 3","key":"10.1016\/j.jsps.2022.10.002_b0350","first-page":"S84","article-title":"Mucus, mucins, and cystic fibrosis","volume":"54","author":"Morrison","year":"2019","journal-title":"Pediatr Pulmonol."},{"issue":"47","key":"10.1016\/j.jsps.2022.10.002_b0355","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc5911","article-title":"Engineered mutant \u03b1-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis\u2013based cell and mice models","volume":"6","author":"Mukherjee","year":"2020","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0360","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/imcb.12230","article-title":"Widespread alterations in the peripheral blood innate immune cell profile in cystic fibrosis reflects lung pathology","volume":"97","author":"Mulcahy","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jsps.2022.10.002_b0365","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13223-020-00454-w","article-title":"Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?","volume":"16","author":"M\u00fcmmler","year":"2020","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"14","key":"10.1016\/j.jsps.2022.10.002_b0370","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1016\/S0021-9258(18)83189-1","article-title":"A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases","volume":"264","author":"Murao","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.jsps.2022.10.002_b0375","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab Treatment in Patients with Severe Eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jsps.2022.10.002_b0380","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines chronic Medications for Maintenance of Lung Health","volume":"176","author":"Patrick","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0385","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0390","doi-asserted-by":"crossref","first-page":"L687","DOI":"10.1152\/ajplung.00304.2016","article-title":"B cells in chronic obstructive pulmonary disease: moving to center stage","volume":"311","author":"Polverino","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.jsps.2022.10.002_b0395","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jsps.2022.10.002_b0400","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jcf.2018.01.010","article-title":"Cystic fibrosis epithelial cells are primed for apoptosis as a result of increased Fas (CD95)","volume":"17","author":"Qiwei","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jsps.2022.10.002_b0405","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.jsps.2022.10.002_b0410","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","article-title":"KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa","volume":"17","author":"Raksha Jain","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.jsps.2022.10.002_b0415","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.jsps.2022.10.002_b0420","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/ajrccm.153.5.8630593","article-title":"Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis","volume":"153","author":"Robinson","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4922","key":"10.1016\/j.jsps.2022.10.002_b0425","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.2772657","article-title":"Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping","volume":"245","author":"Rommens","year":"1989","journal-title":"Science"},{"issue":"Pt5","key":"10.1016\/j.jsps.2022.10.002_b0430","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1469-1809.2003.00028.x","article-title":"The phenotypic consequences of CFTR mutations","volume":"67","author":"Rowntree","year":"2003","journal-title":"Ann. Hum. Genet."},{"key":"10.1016\/j.jsps.2022.10.002_b0435","first-page":"690","article-title":"Novel therapeutic approaches for the management of cystic fibrosis","volume":"15","author":"Ryan","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0440","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s42399-021-00756-z","article-title":"The Epidemiology of Cystic Fibrosis in Arab Countries: A Systematic Review","volume":"3","author":"Samer","year":"2021","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0445","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1007\/s00018-020-03540-9","article-title":"Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations","volume":"77","author":"Samuel","year":"2020","journal-title":"Cell Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.jsps.2022.10.002_b0450","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18176\/jiaci.0254","article-title":"Dupilumab: A New Paradigm for the Treatment of Allergic Diseases","volume":"28","author":"Sastre","year":"2018","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.jsps.2022.10.002_b0455","first-page":"1633","article-title":"Allergic bronchopulmonary aspergillosis successfully treated with benralizumab, The Journal of Allergy and Clinical Immunology","volume":"7","author":"Seiko","year":"2019","journal-title":"In Practice"},{"key":"10.1016\/j.jsps.2022.10.002_b0460","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coph.2018.09.007","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis","volume":"43","author":"Shei","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6416","key":"10.1016\/j.jsps.2022.10.002_b0465","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/362160a0","article-title":"Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties","volume":"362","author":"Sheppard","year":"1993","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jsps.2022.10.002_b0470","first-page":"319","article-title":"Insights on the application of MATLAB and chaotic principles to determine the targeted delivery of a smart drug delivery system against cancer in the experimental phase: A prospective approach","volume":"14","author":"Sivakumar","year":"2020","journal-title":"Asian J. Pharm."},{"issue":"8","key":"10.1016\/j.jsps.2022.10.002_b0475","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/j.1572-0241.2000.02244.x","article-title":"A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency","volume":"95","author":"Stern","year":"2000","journal-title":"Am. J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.jsps.2022.10.002_b0480","first-page":"e9684","article-title":"Mepolizumab as possible treatment for allergic bronchopulmonary aspergillosis: A review of eight cases","volume":"12","author":"Tolebeyan","year":"2020","journal-title":"Cureus."},{"key":"10.1016\/j.jsps.2022.10.002_b0485","doi-asserted-by":"crossref","first-page":"a009472","DOI":"10.1101\/cshperspect.a009472","article-title":"The cystic fibrosis gene: a molecular genetic perspective","volume":"3","author":"Tsui","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jsps.2022.10.002_b0490","doi-asserted-by":"crossref","first-page":"920066","DOI":"10.3389\/fped.2022.920066","article-title":"Severe pediatric asthma therapy: Mepolizumab","volume":"10","author":"Ullmann","year":"2022","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.jsps.2022.10.002_b0495","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jcf.2012.12.005","article-title":"CFTR-mutation specific applications of CFTR-directed monoclonal antibodies","volume":"12","author":"van Meegen","year":"2013","journal-title":"J. Cyst. Fibros."},{"issue":"23","key":"10.1016\/j.jsps.2022.10.002_b0500","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"A novel anti-interleukin-6 monoclonal antibody, for Castleman's disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jsps.2022.10.002_b0505","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell."},{"issue":"5","key":"10.1016\/j.jsps.2022.10.002_b0510","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11882-011-0210-y","article-title":"The potential role of interleukin-17 in severe asthma","volume":"11","author":"Wang","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"issue":"7","key":"10.1016\/j.jsps.2022.10.002_b0515","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jsps.2022.10.002_b0520","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.4049\/jimmunol.181.8.5481","article-title":"NKG2D is critical for NK cell activation in host defense against Pseudomonas aeruginosa respiratory infection","volume":"181","author":"Wesselkamper","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jsps.2022.10.002_b0525","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.alit.2020.07.005","article-title":"Benralizumab as initial treatment for chronic eosinophilic pneumonia","volume":"70","author":"Yazawa","year":"2021","journal-title":"Allergol. Int."},{"key":"10.1016\/j.jsps.2022.10.002_b0530","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-019-0397-3","article-title":"Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series","volume":"16","author":"Zhang","year":"2020","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.jsps.2022.10.002_b0535","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3389\/fimmu.2020.01142","article-title":"T Cells in Fibrosis and Fibrotic Diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jsps.2022.10.002_b0540","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000029497","article-title":"Genotype and phenotype in cystic fibrosis","volume":"67","author":"Zielenski","year":"2000","journal-title":"Respiration"},{"key":"10.1016\/j.jsps.2022.10.002_b0545","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","article-title":"Cystic fibrosis: genotypic and phenotypic variations","volume":"29","author":"Zielenski","year":"1995","journal-title":"Annu. Rev. Genet."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S131901642200250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S131901642200250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:27:33Z","timestamp":1736166453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S131901642200250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S131901642200250X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2022.10.002","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targets for cystic fibrosis and therapeutic potential of monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}